Pay in 4 interest-free payments of $5.35 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
At 208 weeks, semaglutide was associated with mean reduction in weight (10.2%), waist circumference (7.7 cm) and waist-to-height ratio (6.9%) versus placebo (1.5%, 1.3 cm and 1.0%, respectively
received a growth investment from Great Point Partners, though the exact amount isnt specified
Pharma companies and healthcare stakeholders should closely monitor these conversations as leading indicators for potential regulatory and market shifts
Kulak MV, Cyr AR, Woodfield GW, Bogachek M, Spanheimer PM, Li T, Price DH, Domann FE, Weigel RJ
Semaglutide is a GLP-1 receptor agonist that targets appetite regulation and blood sugar balance
